Delivering New Hope to Prevent Cancer Recurrence in Breast Cancer Patients
NCT04434040 · RecruitingThis study looks at how two medicines, atezolizumab and sacituzumab govitecan, work together to help prevent cancer from coming back in patients with triple negative breast cancer. The goal is to see if this combination is effective for patients who still have some cancer after treatment. Participants will receive treatment for 18 weeks and be followed for three years to monitor their progress.
Locations and contact
This trial is running at 7 locations in the United States. 4 of them are currently recruiting.
United States7 locations · 4 recruiting
- Dana-Farber Cancer InstituteBoston, MassachusettsRecruiting
- University of California San FranciscoSan Francisco, CaliforniaRecruiting
- University of Pennsylvania-Abramson Cancer CenterPhiladelphia, PennsylvaniaRecruiting
- Vanderbilt-Ingram Cancer CenterNashville, TennesseeRecruiting
- University of Chicago Comprehensive Cancer Center at Silver Cross HospitalNew Lenox, IllinoisWithdrawn
- University of Chicago Medical CenterChicago, IllinoisWithdrawn
- University of Chicago Medical Center for Advanced Care Orland ParkOrland Park, IllinoisWithdrawn
Who can join
This trial is open to men and women aged 18 and older. To join, participants must have confirmed residual breast cancer after receiving chemotherapy. They should also have specific test results related to hormone receptors and HER2 status. Additionally, participants need to show evidence of cancer DNA in their blood after their initial treatments. The trial team will confirm who can join.
What happens during the trial
Everyone in the study will receive the combination of atezolizumab and sacituzumab govitecan. Treatment will last for 18 weeks, given over six cycles. Atezolizumab will be given through an IV on day 1 of each cycle, while sacituzumab govitecan will be given on days 1 and 8 of each cycle. Participants will regularly visit the clinic for follow-ups.
The trial team
The trial is led by the Dana-Farber Cancer Institute, with Dr. Elizabeth A Mittendorf as the principal investigator. Collaborators include Genentech, Inc. and Stand Up To Cancer.
Important dates
The trial started on July 2, 2020. It is currently recruiting new participants and is expected to finish by December 30, 2027.
Additional information
The trial's ID number is NCT04434040. It is a Phase 2 study, which means it is testing how well the treatment works and how safe it is. The FDA regulates this study, and about 40 participants are expected to join.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →